Normalization of GRK2 protein and mRNA measures in patients with depression predict response to antidepressants

International Journal of Neuropsychopharmacology

Volumn 13, Issue 1, 2010, Pages 83-91

  Matuzany Ruban, Angela ^a   Golan, Moran ^a   Miroshnik, Nataly ^b   Schreiber, Gabriel ^a,b   Avissar, Sofia ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BARZILAI MEDICAL CENTER   (Israel)

Author keywords

Antidepressant; GRK2; Mood disorders; Post receptor signal transduction; Receptor desensitization

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; G PROTEIN COUPLED RECEPTOR KINASE 2; MESSENGER RNA; MONOCLONAL ANTIBODY; VENLAFAXINE;

ADULT; ARTICLE; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; FEMALE; HUMAN; IMMUNOBLOTTING; MAJOR DEPRESSION; MALE; MONONUCLEAR CELL; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS; BIOMARKERS, PHARMACOLOGICAL; CITALOPRAM; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; FEMALE; G-PROTEIN-COUPLED RECEPTOR KINASE 2; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 77949657777     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709000364     Document Type: Article

References (36)

1. Alesci S, Martinez PE, Kelkar S, Ilias I, et al. (2005). Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. Journal of Clinical Endocrinology and Metabolism 90, 2522-2530.
2. Avissar S, Matuzany-Ruban A, Tzukert K, Schreiber G (2004). b-arrestin levels: reduced in leukocytes of patients with depression and elevated by antidepressants in rat brain. American Journal of Psychiatry 161, 2066-2072.
3. Avissar S, Nechamkin Y, Roitman G, Schreiber G (1997). Reduced G protein functions and immunoreactive levels in mononuclear leukocytes of patients with depression. American Journal of Psychiatry 154, 211-217.
4. Avissar S, Schreiber G, Nechamkin Y, Neuhaus I, et al. (1999). The effects of seasons and light therapy on G protein levels in mononuclear leukocytes of patients with seasonal affective disorder. Archives of General Psychiatry 56, 178-183.
5. Barrett TB, Hauger RL, Kennedy JL, Sadovnick AD, et al. (2003). Evidence that a single nucleotide polymorphism in the promoter of the G protein receptor kinase 3 gene is associated with bipolar disorder. Molecular Psychiatry 8, 546-547.
6. Benovic JL, Mayor F, Somers RL, Caron MG, et al. (1986). Light-dependent phosphorylation of rhodopsin by beta-adrenergic receptor kinase. Nature 321, 869-872.
7. Cowen DS (2007). Serotonin and neuronal growth factors-a convergence of signaling pathways. Journal of Neurochemistry 101, 1161-1171.
8. Fan J, Malik AB (2003). Toll-like receptor-4 (TLR4) signaling augments chemokine-induced neutrophil migration by modulating cell surface expression of chemokine receptors. Nature Medicine 9, 315-321.
9. Garcia-Sevilla JA, Escriba PV, Ozaita A, La Harpe R, et al. (1999). Up-regulation of immunolabeled alpha2A-adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. Journal of Neurochemistry 72, 282-291.
10. Garcia-Sevilla JA, Ventayol P, Perez V, Rubovszky G, et al. (2004). Regulation of platelet alpha 2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. Neuropsychopharmacology 29, 580-588.
11. Grange-Midroit M, Garcia-Sevilla JA, Ferrer-Alcon M, La Harpe R, et al. (2003). Regulation of GRK 2 and 6, beta-arrestin-2 and associated proteins in the prefrontal cortex of drug-free and antidepressant drug-treated subjects with major depression. Brain Research Molecular Brain Research 111, 31-41.
12. Lefkowitz RJ, Caron MG, Hausdorff WP (1990). Role of phosphorylation in desensitization of the beta-adrenoceptor. Trends in Pharmacological Sciences 11, 190-194.
13. Lombardi MS, Kavelaars A, Schedlowski M, Bijlsma JW, et al. (1999). Decreased expression and activity of
14. G-protein-coupled receptor kinases in peripheral blood mononuclear cells of patients with rheumatoid arthritis. FASEB Journal 13, 715-725.
15. Luttrell LM, Lefkowitz RJ (2002). The role of beta-arrestins in the termination and transduction of G protein-coupled receptor signals. Journal of Cell Science 115, 455-465.
16. Maes M, Meltzer HY, Bosmans E, Bergmans R, et al. (1995). Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. Journal of Affective Disorders 34, 301-309.
17. Matuzany-Ruban A, Avissar S, Schreiber G (2005). Dynamics of beta-arrestin1 protein and mRNA levels elevation by antidepressants in mononuclear leukocytes of patients with depression. Journal of Affective Disorders 88, 307-312.
18. Metaye T, Gibelin H, Perdrisot R, Kraimps JL (2005). Pathophysiological roles of G-protein-coupled receptor kinases. Cellular Signaling 17, 917-928.
19. Miralles A, Asensio VJ, Garcia-Sevilla JA (2002). Acute treatment with the cyclic antidepressant desipramine, but not fluoxetine, increases membrane-associated G protein-coupled receptor kinases 2/3 in rat brain. Neuropharmacology 43, 1249-1257.
20. H1 Responses in Multiple Sclerosis. Archives of Neurology 58, 1081-1086.
21. Mohr DC, Hart SL, Julian L, Tasch ES (2007). Screening for depression among patients with multiple sclerosis: two questions may be enough. Multiple Sclerosis 13, 215-219.
22. Niculescu AB, Segal DS, Kuczenski R (2000). Identifying a serious of candidate genes for mania and psychosis: a convergent functional genomics approach. Physiological Genomics 9, 83-91.
23. Palczewski K (1997). GTP-binding-protein-coupled receptor kinases-two mechanistic models. European Journal of Biochemistry 248, 261-269.
24. Pitcher JA, Freedman NJ, Lefkowitz RJ (1998). G protein-coupled receptor kinases. Annual Review of Biochemistry 67, 653-692.
25. Premont RT, Gainetdinov RR (2007). Physiological roles of G protein-coupled receptor kinases and arrestins. Annual Review of Physiology 69, 511-534.
26. Reiter E, Lefkowitz RJ (2006). GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends in Endocrinology and Metabolism 17, 159-165.
27. Ribas C, Penela P, Murga C, Salcedo A, et al. (2007). The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in GPCR regulation and signaling. Biochimica et Biophysica Acta 1768, 913-922.
28. Schiffer RB, Winema NM (1990). Antidepressant pharmacotherapy of depression associated with multiple sclerosis. American Journal of Psychiatry 147, 1493-1497.
29. Schreiber G, Avissar S (2006). The involvement of G proteins and regulators of receptor-G protein coupling in the pathophysiology, diagnosis and treatment of mood disorders. Clinica Chimica Acta 366, 37-47.
30. Schreiber G, Avissar S (2007). Regulators of GPCR-G protein coupling: Antidepressants mechanism of action and pathophysiological mechanisms in mood disorders. Expert Review of Neurotherapeutics 7, 75-84.
31. Tanis KQ, Duman RS (2007). Intracellular signaling pathways pave roads to recovery for mood disorders. Annals of Medicine 39, 531-544.
32. Vroon A, Kavelaars A, Limmroth V, Lombardi MS, et al. (2005). G protein-coupled receptor kinase 2 in multiple sclerosis and experimental autoimmune encephalomyelitis. Journal of Immunology 174, 4400-4406.
33. Weiss ER, Raman D, Shirakawa S, Ducceschi MH, et al. (1998). The cloning of GRK7, a candidate cone opsin kinase, from cone-and rod-dominant mammalian retinas. Molecular Vision 4, 27-35.
34. Wells KB, Golding JM, Burnam MA (1988). Psychiatric disorder in a sample of the general population with and without chronic medical conditions. American Journal of Psychiatry 145, 976-981.
35. Wells KB, Golding JM, Burnam MA (1989). Affective, substance use, and anxiety disorders in persons with arthritis, diabetes, heart disease, high blood pressure, or chronic lung conditions. General Hospital Psychiatry 11, 320-327.
36. Wu H, Wei W, Song L, Zhang L, et al. (2007). Paeoniflorin induced immune tolerance of mesenteric lymph node lymphocytes via enhancing beta 2-adrenergic receptor desensitization in rats with adjuvant arthritis. International Immunopharmacology 7, 662-673.